Nektar Therapeutics | $NKTR Stock | Shares Surge Over 15% On Positive Trial Data For NKTR-181

0
123
Nektar Therapeutics
Share this:Share on FacebookTweet about this on TwitterPin on PinterestShare on Google+Email this to someone

Nektar Therapeutics (NASDAQ: NKTR)

 

 

Nektar Therapeutics News

On Monday before the market opened, Nektar Therapeutics announced that they received positive results from NKTR-181, an opioid analgesic, that was developed to provide strong pain relief while eliminating the “high levels of euphria” that often contributes to patients becoming addicted and/or abusing the treatment.

This is great news and something to keep an eye on as further testing takes place in the future. Pain killers have grown to be a major problem in the US as addiction and abuse can often lead to death.

 

NKTR Technicals

Nektar Therapeutics

 

Shares of NKTR are looking to gap up over 20% following the positive news of NKTR-181 with premarket highs currently at $19.50 after closing Friday at $15.50. This has a little bit higher share price than the penny stocks I like to trade but it should still provide plenty of opportunity.

There is a key pivot level at $20 so look for some hesitation there but after that we have room up to $22.50. This should be a very active stock with high relative volume as this gapper will be hitting a lot of trader’s radars this morning, so expect increased volatility and possibly wider spreads than normal as prices work themselves out at the open.

 

Comments

“The data from this efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential study,”

said clinical investigator Martin Hale, M.D., medical director of Gold Coast Research.

“While standard opioid analgesics, including abuse-deterrent formulations, have been the most effective way to treat chronic pain, they are associated with serious safety concerns and many opioid-naïve patients fear taking them because of the potential for abuse and addiction.  The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally change how we treat patients with chronic pain conditions.”

 

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology.

It provides small molecule drugs, peptides and other potential biologic drug candidates. It’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA. –MarketWatch

Check out our new trading chat rooms if you’re interested in learning more.

 

IMAGE CREDIT

SHARE
Previous articleEconomic Calendar & Watch List 3/17/2017
Next articleEconomic Calendar & Watch List 3/20/2017
Mike Herman Mike graduated from the Florida State University with a Real Estate and Bachelor of Finance degree and focused particularly in the field of Behavioral Finance. During his time at the Florida State University, Mike began to trade equities and quickly realized the opportunities that existed in the markets. Through trading, Mike had facilitated relationships with a few very experienced individuals who had an expertise in the private equity field. More specifically, the private funding of small cap start-up companies. After several years of successful deals as a venture capitalist, Mike made the decision to return to work as an independent trader. Throughout the past 7 years of working as an independent trader, Mike has refined his strategy to focus on news driven momentum while factoring in market sentiment and psychology with an emphasis on proper risk management. Mike possesses a unique ability to rapidly decipher critical market moving news and take appropriate action. You can contact Mike at mike@warriortradingnews.com Legal Disclaimer – This is not meant to be a recommendation to buy or to sell securities nor an offer to buy or sell securities. Before selling or buying any stock or other investment you should consult with a qualified broker or other financial professional. The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author has no business relationship with any company whose stock is mentioned in this article nor is receiving compensation from any of the companies mentioned.

NO COMMENTS